<DOC>
	<DOCNO>NCT02243189</DOCNO>
	<brief_summary>The purpose study investigate cytokine level nasal lavage gene expression nasal scrap follow single nasal dose JNJ-43260295 healthy participant , atopic mild mild-persistent asthmatic ( breathe disorder wheeze difficulty breathe ) participant without nasal allergen challenge prior dose .</brief_summary>
	<brief_title>Study Examine Cytokine Levels , Gene Expression Safety Single Nasal Dose JNJ-43260295 , Healthy Participants , Atopic Participants With Mild Mild-Persistent Asthma</brief_title>
	<detailed_description>This study consist 2 part . In first part , healthy adult participant receive single nasal dose JNJ-43260295 placebo double blind ( participant investigator know whether participant assign receive study medication placebo ) , randomize ( study medication placebo assign participant chance ) , placebo-controlled ( study experimental treatment procedure compare placebo ) setting . In second part , open label ( participant investigator aware treatment , participant receive ) , atopic participant mild mild-persistent asthma participate 3 consecutive treatment period ( Period 1 , 2 , 3 ) . In Period 1 , participant receive single nasal dose JNJ-43260295 without prior nasal allergen challenge . In Period 2 , participant receive single nasal dose JNJ-43260295 , precede nasal allergen challenge approximately 15 hour prior JNJ-43260295 dosing . In Period 3 , participant receive single nasal allergen challenge without JNJ-43260295 . There washout period least 21 day 3 consecutive treatment period . Cytokine level nasal lavage gene expression nasal scrap primarily evaluate treatment period . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>A . Healthy Participants Atopic Mild MildPersistent Asthmatic Participants : Participants must nonsmoker nonregular smoker ( 1 2 cigarette weekend part social gathering ) least 3 month prior Screening , accord participant 's selfreported medical history . Participants willing ( continue ) abstain smoke Screening completion last study relate activity Participants must body mass index ( BMI : weight kilogram [ kg ] divide height square meter [ m^2 ] ) 18.0 30.0 kg/m^2 , extremes included Participants must normal 12lead electrocardiogram ( ECG ) Screening include normal sinus rhythm ( heart rate 40 100 beat per minute [ bpm ] ) ; QT interval correct heart rate accord Fridericia ( QTcF ) interval less equal ( &lt; = ) 450 millisecond ( m ) ; QRS interval low 120 m ; PR interval &lt; =220 m Participants must healthy , exception finding relate asthma allergy atopic mild mildPersistent asthmatic participant , basis medical evaluation reveals absence clinically relevant abnormality include physical examination , medical history , vital sign ( Systolic Blood Pressure [ BP ] , Diastolic BP , pulse rate , respiratory rate , body temperature ) , result blood biochemistry hematology test perform Screening Participants must willing/ able adhere prohibition restriction specify protocol study procedure B. Atopic Mild MildPersistent Asthmatic Participants : Participants Investigatordiagnosed mild mildpersistent asthma base Guidelines Diagnosis Management Asthma Participants wellestablished allergen profile ( participant previously skin test , history , allergic response specific allergen ) Participants force expiratory volume 1 second ( FEV1 ) great ( &gt; ) 70 percent ( % ) predict Baseline A . Healthy Participants Atopic Mild MildPersistent Asthmatic Participants : Participants significant ( assessment Investigator ) nasal abnormality and/or history nasal sinus surgery within 12 month enrollment Participants upper low respiratory tract infection within 4 week enrollment Participants history evidence use alcohol , barbiturate , amphetamine , recreational narcotic drug use within past 1 year , Investigator 's opinion would compromise participant 's safety and/or compliance study procedures Participants know history human immunodeficiency virus type 1 ( HIV1 ) HIV2 infection , know history hepatitis A , B , C virus infection study Screening Female participant breastfeed Screening positive urine pregnancy test Screening B. Atopic Mild MildPersistent Asthmatic Participants : Hospitalization treatment emergency care facility asthma last 3 year Participants use nasal corticosteroid daily basis 4 week prior enrollment Participants receive allergen immunotherapy last 2 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Asthma</keyword>
	<keyword>JNJ-43260295</keyword>
	<keyword>Nasal Allergen Challenge</keyword>
</DOC>